Will Noxopharm get Traction from Endocyte Sale?, page-8

Hi Roger.... well, only Graham Kelly can truly answer your question.

But after all the blood sweat and tears that he has expended over the years to get to this point.... I am positive that whatever decisions have to made down the road.... the shareholders interests will always be his priority.

In any event... I’m not at all sure that your question about whether he will “sell” is even likely to happen. The potential for Veyonda lies across a number of different fields.... and looking into the future is always a rather misty vision... but I see the future as being a series of collaborative events with big Pharma coming in to fund certain trials that fit their own agenda.

The company I’m sure will have it’s roots for a long while in Oz.... but if we are to grow into our full potential.... also including all of the Nyrada drugs too of course..... then the bigger game will have to played out in the USA. That’s where the big investment community resides.

Veyonda and the various trials that are currently being run are our best bet for an early recognition of what this company can do. But further to that.... the three embryo technologies in Nyrada are going to get a lot of attention once (a) Veyonda starts to make its mark.... and (b) when the market starts to appreciate just what a valuable set of medical fields the three Nyrada drugs span. Anti cholesterol, brain damage protection.... and a stealth weapon in the form of an anti inflammatory drug.

No.... I don’t believe that “selling” as such will be a major objective..... but out- licensing and big Pharma investment participation is the most like path in my view. If you’re concerned that the company might lose some of its Aussie drive..... I don’t think you have to worry too much, as long as Dr K is directing the operations.

Apples